Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 695.46

+2.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2733)	10/16/2019 1:44:34 AM
From: Miljenko Zuanic	Read Replies (2) of 3557

Lucentis 3Q US sale (Roche) are at $442M, reduced relative to 2Q of $467M. REGN usually record increase in Eylea 3Q v 2Q US sale, so hope it will report also in 2019-3Q. Projecting US sale of $1180M (there was some disruption in avastin availability from compounding pharmacies, so maybe even $$$$ more for 3Q???).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next